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Abstract
The lymphatic vasculature plays a pivotal role in maintaining tissue fluid homeostasis, immune
surveillance, and lipid uptake in the gastrointestinal organs. Therefore, impaired function of the
lymphatic vessels caused by genetic defects, infection, trauma, or surgery leads to the abnormal
accrual of lymph fluid in the tissue and culminates in the swelling of affected tissues, known as
lymphedema. Although millions of people suffer from lymphedema worldwide which causes
impaired wound healing, compromised immune defense and, in rare case, lymphangiosarcoma, no
effective therapy is currently available. In addition, recent advances in cancer biology have
disclosed an indispensable function of the lymphatic vessel in tumor growth and metastasis.
Therefore, understanding the detailed mechanisms governing lymphatic vessel formation and
function in pathophysiologic conditions is essential to prevent or treat these diseases. Here, we
will review the developmental processes of the lymphatic vessels and postnatal lymphatic
neovascularization, focusing on the role of recently identified bone-marrow (BM) derived
PODOPLANIN expressing (PODOPLANIN+) cells as lymphatic endothelial progenitor cells
(LEPCs).
Introduction
The vasculature, which includes the blood vessels and the lymphatic vessels, is
indispensable for the development and the survival of mammals. Extensive efforts have been
made to study the biology of blood vessels; however, recent investigations on the molecular
mechanisms controlling the development of the lymphatic vessels during embryogenesis and
the diseases related to lymphatic dysfunctions have gained much attention. In the adult, the
lymphatic vasculature is composed of three distinct yet interconnected parts: lymphatic
capillaries, precollectors, and lymphatic collecting vessels. The lymphatic capillaries are
single-layered vessels consisting of staggered LECs, which lack mural cells and are
surrounded by few basement membranes. The LECs of the lymphatic capillaries are
anchored to extracellular matrix by anchoring filaments. These features allow the lymphatic
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capillaries to have a high permeability to macromolecules as well as interstitial fluids. In
contrast to the LECs in the capillaries, precollectors and collecting vessels are surrounded by
smooth muscle cells and contain valves that maintain the unidirectional transport of the
lymphatic fluids toward the blood vessels. Eventually, the collecting lymphatic vessels carry
the lymphatic fluid to the blood system through the jugular and subclavian veins, where
blood vessels and lymphatic vessels, in the adult, are connected.
The primary function of the lymphatic vessels is to maintain tissue fluid homeostasis and
lipid uptake. In addition, the lymphatic vessels play a critical role in immune surveillance by
transporting foreign substances to the lymph nodes, where T or B lymphocytes reside.
Recent studies suggest that the lymphatic vessel regeneration can also be an integral part of
wound healing process (Cho et al., 2006; Niessen et al., 2011). Furthermore, defects in the
lymphatic vessels can lead to diseases, such as lymphedema, accompanied by several
complications, including dermal fibrosis, impaired wound healing, and enhanced
susceptibility to infection. Additionally, lymphatic vessels facilitate tumorigenesis by
providing a route for tumor metastasis. Here, we will review the development of lymphatic
vessels and discuss the potential usage of BM-derived cells for disease-related lymphatic
dysfunctions.
Development of lymphatic vasculature
In developing mouse embryos, specification and differentiation of LECs begin with the
expressions of SOX-18, a member of the SOX (Sry-related HMG box) transcription factor
family, and PROX-1, a prospero homeobox transcription factor. Sox18 is expressed as early
as embryonic day (E) 9 in a subset of cardinal veins. Then, shortly after, cells co-expressing
Sox18 and Prox1 appear and dorsolaterally migrate out to form the lymphatic sacs (Francois
et al., 2008; Wigle and Oliver, 1999). While overexpressing SOX-18 significantly induces
the expression of LEC markers, such as Prox1, ephrinB2, and Vegfr3, Sox18 deficient mice
display embryonic lethality with abnormal patterning of the lymphatic vessels (Francois et
al., 2008). In fact, SOX-18 can directly bind to the promoter and induce the expression of
Prox1, which is the master switch for LEC development. A Prox1−/− mice study shows that
PROX-1 appears to be dispensable for the initiation of LEC generation, but essential for
budding and sprouting of the LECs (Wigle et al., 2002; Wigle and Oliver, 1999). PROX1
can also provide the identity of LECs to blood endothelial cells (BECs), and is continuously
required for the maintenance of LEC identity by expressing LEC markers and blocking the
expression of BEC genes (Hong et al., 2002; Johnson et al., 2008; Petrova et al., 2002).
Recent studies show that COUP-TFII, an orphan nuclear receptor, can also interact with
SOX18 to activate and maintain the expression of PROX1; it can also regulate PROX1
downstream targets (Lee et al., 2009; Yamazaki et al., 2009). This SOX18-COUP-TFII-
PROX1 complex plays a critical role in the initiation and maintenance of the lymphatic
vasculature throughout life.
The VEGFC and VEGFR3 pathway is a critical regulator for a proper migration/sprouting of
LECs to form a lymphatic sac. Around E10.5, VEGFC is expressed in the mesenchymal
cells around the jugular veins, from which the first arising LECs sprout and migrate
(Karkkainen et al., 2004). Consistent with the expression pattern of VEGFC and VEGFR3,
genetic knockout mice studies reveal an indispensable role of this pathway in the
development of lymphatic vasculature. In Vegfc−/− mice, PROX1+ LECs develop normally;
however, they are unable to migrate out of the cardinal veins and cause a failure in the
formation of lymphatic sacs. This suggests that VEGFC plays a critical role in the migration
of LECs (Karkkainen et al., 2004). Due to a severe cardiovascular defect, Vegfr3−/− mice
die prior to LEC development (Dumont et al., 1998), precluding the investigation of
VEGFR3 function in the process. More recently, a study showed that a kinase activity is
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required for the sprouting of LECs, and ligand binding domain is critical for the proliferation
of already formed lymphatic sacs (Zhang et al., 2010).
PODOPLANIN is a 38 kD integral membrane mucoprotein and is predominantly expressed
in the endothelium of lymphatic capillaries. Podoplanin deficient mice die at birth due to
respiratory failure, and manifest malfunctioning lymphatic vessels and congenital
lymphedema (Schacht et al., 2003). Recently, PODOPLANIN has gained much attention as
a critical regulator of the separation between blood vessels and lymphatic vessels.
PODOPLANIN can induce aggregation and activation of platelets by binding to CLEC-2
receptor on platelets (Bertozzi et al., 2010; Kato et al., 2003; Suzuki-Inoue et al., 2010;
Uhrin et al., 2010). The failure of platelet aggregation, in the absence of Podoplanin, causes
the development of a mixed lympho-blood vessels (Bertozzi et al., 2010; Uhrin et al., 2010),
which phenocopies the defects seen in Syk−/−, Slp76−/− or PLCg2−/− mice (Abtahian et al.,
2003; Ichise et al., 2009). The inactivation of Slp76 in platelets and megakaryocytes results
in the generation of mixed lympho-blood vessels (Bertozzi et al., 2010), suggesting that, at
least, SPL76 is needed in platelets to signal the PODOPALNIN-CLEC2 interaction, which
induces the separation of blood and lymphatic vessels. Further maturation and remodeling of
the lymphatic sacs into functional lymphatic vessels, consisting of collecting lymphatic
vessels and lymphatic capillaries, are regulated by several key molecules, such as FOXC2,
EphB2 and Tie1-Ang2. Out of these key molecules, FOXC2, a fork head transcription
factor, notably plays a critical role in the formation of functional collecting lymphatic
vessels, as demonstrated by defective valve formation and aberrantly increased recruitment
of pericytes in Foxc2−/− mice (Petrova et al., 2004). Mechanistically, NFATc is one of direct
downstream targets of FOXC2 for the lymphatic vessel maturation (Norrmen et al., 2009).
Connexins 37 and 43 appear to be other targets of FOXC2 to regulate the valve formation in
the collecting lymphatic vessels (Kanady et al., 2011). For further discussion about
lymphatic vessel development, please read previously published literatures (Karpanen and
Alitalo, 2008; Tammela and Alitalo, 2010).
BM as a potential source of lymphatic endothelial cells
BM cells participate in many different pathophysiologic processes, including hematopoiesis,
angiogenesis, and inflammation. The contribution of BM-derived cells to non-hematopoietic
tissues, such as neuroectodermal cells, skeletal myoblasts, and cardiomyocytes, has been
reported (Krause, 2002), which was later highly debated (Spyridonidis et al., 2005). On the
other hand, the role of hematopoietic stem cells (HSCs) and endothelial progenitor cells
(EPCs), derived from BM for blood vessel formation, is largely accepted (Asahara et al.,
2011). This has raised a question as to whether LEPCs can also be derived from BM as well.
Similar to blood vessels, the formation of lymphatic vessels (lymphatic neovascularization)
is achieved by two interdependent ways: lymphangiogenesis (the formation of new
lymphatic vessels from preexisting lymphatic vasculature) and lymphvasculogenesis (de
novo generation of lymphatic vessel through stem or progenitor cells). It had been believed
that lymphatic vessels in the adult were generated exclusively by lymphangiogenesis (Cao et
al., 2006; He et al., 2004; Karkkainen et al., 2004; Karpanen et al., 2001; Nagy et al., 2002);
however, recent studies have provided compelling evidence that lymphvasculogenesis may
also contribute to new lymphatic vessel formation (Kerjaschki et al., 2006; Maruyama et al.,
2005; Religa et al., 2005; Salven et al., 2003). First potential evidence of LEPCs in
hematopoietic organs was reported by Salven et al, that a subpopulation of human fetal liver
co-expresses CD34, VEGFR3 and CD133 (AC133) (Salven et al., 2003). In culture, this
specific cell population displays a robust proliferative potential, becomes adherent, and
expresses other lymphatic markers, such as LYVE-1 and PODOPLANIN, and blood
endothelial markers, such as VE-cadherin and CD105, suggesting the dual potential of these
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cells as LEPC and EPC. This initial finding was further corroborated by subsequent studies.
Two groups showed that, using BM transplantation, donor-derived GFP+ cells were found
closely localized or incorporated in the newly formed lymphatic vessels under inflammatory
conditions (Maruyama et al., 2005; Religa et al., 2005). A more compelling evidence was
provided by Kerjaschki et al (2006), in which the presence of male donor-derived LECs in
the lymphatic vessels was clearly revealed in the transplanted kidneys of female recipients
(Kerjaschki et al., 2006). Together, these studies strongly support the notion that
lymphvasculogenesis, via precursor cells of lymphatic vessels derived from either BM or
other organs, can play crucial roles in new lymphatic vessel formation during postnatal
period. Nevertheless, these studies failed to address the identity and characteristics of the
cells that contributed to the postnatal lymphvasculogenesis, namely lymphatic endothelial
progenitor cells (LEPCs).
Some tissue macrophages express lymphatic markers, such as LYVE-1 and PROX-1, and
secrete VEGFC (Cursiefen et al., 2004; Maruyama et al., 2005). A recent report showed that
CD11b+ cells were found in the sites of lymphangiogenesis in cornea undergoing
inflammation (Maruyama et al., 2005). The depletion of macrophages by clodronate
liposomes resulted in a suppression of lymphangiogenesis with concomitant decrease in
recruited CD11b+ cells, suggesting that CD11b+ cells can play an important role in
inflammation-induced lymphangiogenesis. However, this study was not able to show direct
evidence that macrophages are physically incorporated into the lymphatic vessels. By taking
advantage of genetic lineage tracing strategy, Zumsteg et al (2009) have provided
compelling evidence that BM-derived myelomonocytic lineage cells can contribute to new
lymphatic vessels through lymphvasculogenesis (Zumsteg et al., 2009). In Rip1Tag2 mice
undergoing pancreatic cell carcinogenesis, peritumoral lymphatic vessels contained GFP+
cells derived from transplanted donor BM cells, some of which coexpressed PROX-1 and
either PODOPLANIN or LYVE-1. Furthermore, the incorporated BM-derived cells in the
lymphatic vessels were shown to be myeloid lineage cells. For this analysis, Rip1Tag2 mice
were reconstituted with BM from either CXCR1+/GFP mice, in which GFP was
preferentially expressed in monocytes under the control of CXCR1, or CD11bCre;Z/EZ
mice, in which cells that have expressed CD11b are permanently marked by GFP expression
via a loxP-Cre recombination. In addition, BM-derived macrophages exhibited significantly
augmented expression of lymphatic markers with concomitant decrease in hematopoietic
CD45 and macrophage marker F4/80 in tube formation assay, supporting the notion that
myelomonocytic lineage cells can transdifferentiate into LECs in newly formed lymphatic
vessels. Collectively, these studies clearly showed the contribution of BM cells to lymphatic
vessels as structural components.
BM-derived PODOPLANIN+ cells can function as LEPCs
Recently, we reported that, a subpopulation of BM cells, PODOPLANIN+ cells function as
LEPCs by transdifferentiating into lymphatic endothelial cells and physically incorporating
into lymphatic vessels under inflammatory and tumorigenic conditions (Lee et al., 2010).
Around 1% of freshly isolated BM mononuclear cells (BM-MNCs) expressed
PODOPLANIN. In culture of BM-MNCs in the presence of lymphatic cytokines (VEGFA
and VEGFC) and EGF, PODOPLANIN+ cells reached ~20%, most of which also expressed
CD11b. Interestingly, the expressions of stem/progenitor markers, such as c-KIT and Sca-1,
were exclusively limited to the PODOPLANIN+ cells, i.e. PODOPLANIN+CD11b+ cells.
Other lymphatic markers, such as VEGFR-3 and LYVE-1, showed the same expression
pattern. When further cultured in LEC medium, the PODOPLANIN+CD11b+ cells exhibited
enhanced LEC marker expression with concomitant loss of CD45, while
PODOPLANIN−CD11b+ cells continued to express CD45 with low expression of LEC
markers, suggesting that progenitor function is almost exclusively restricted to
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PODOPLANIN+CD11b+ cells. Indeed, these cells were able to integrate into newly formed
lymphatic vessels while losing the expression of CD45 in several independent mouse
models, in which lymphatic vessel growth occur, confirming that the
PODOPLANIN+CD11b+ cells include LEPCs. Therefore, it is tempting to speculate that the
expression of PODOPLANIN may confer stem/progenitor potential to certain populations of
BM-MNC-derived CD11b+ cells. A report by Blin-Wakkach (Blin-Wakkach et al., 2006)
showed that the BM-derived B220+CD11b+ cells were induced to differentiate into B
lymphocyte by acquiring B lymphocyte specific genes and losing myeloid specific genes in
response to IL-7 treatment. Another study also demonstrated that the Flt3+CD11b+ cells
generated mature dendritic cells (DCs) (Hieronymus et al., 2005). Interestingly, the
Flt3+CD11b+ cells express stem/progenitor cell markers including CD117 (c-KIT), CD184
(CXCR4), CD93 (Ly68/AA4.1), and CD133 (AC133). When induced to differentiate into
DCs, the expression of those surface antigens significantly decreased, although the
expression of CD11b remained relatively unchanged. These results suggest that CD11b+
cells possess certain plasticity in their function that ranges from stem/progenitor cells to
differentiated cells. Therefore, we envision that CD11b+ myelomonocytes attain expression
of PODOPLANIN upon influence from environmental cues, including lymphangiogenic
cytokines, and become LEPCs, which can subsequently differentiate into lymphatic
endothelial cells. Whether the expression of c-Kit and Sca1 can be also induced by enhanced
PODOPLANIN expression remains to be determined. Alternatively, some c-KIT+CD11b+
progenitor cells in BM can attain the expression of PODOPLANIN upon influence from
environmental cues. The possibility that a rare population of PODOPLANIN+CD11b+c-
KIT+ cells is selectively expanded in response to cytokines can also be possible.
Considering that the axis of SOX18-COUPTFII-PROX1 is critical for lymphatic
specification and maintenance throughout embryogenesis and adult life as discussed above,
it would also be interesting to see if such embryonic program is reactivated in response to
environmental cues and induce a certain fraction of BM cells to adopt lymphatic identity.
Our in vivo cell injection studies demonstrated that culture-isolated PODOPLANIN+ cells
are not only incorporated into lymphatic vessels but also localized perivascularly and
augmented peritumoral lymphatic vascular density (Lee et al., 2010). PODOPLANIN+ cells
showed high pro-proliferative potential as well as high levels of lymphangiogenic cytokines.
Furthermore, PODOPLANIN+ cells could facilitate fusion among newly formed lymphatic
vessels by bridging the ends of the vessels (i.e. lymphatic vascular anastomosis), which lead
to lymphatic neovascularization (Fantin et al., 2010). Together, this evidence implies that
PODOPLANIN+ cells induce new lymphatic vessel growth through both
lymphvasculogenesis and lymphangiogenesis (Figure 1).
Clinical application of BM-derived cells for lymphatic disorders
Lymphedema is a disease caused by insufficiency of functional lymphatic vessels, leading to
a failure of fluid uptake from surrounding tissues. Lymphedema can result from idiopathic
causes or genetic defects, such as genetic mutations in FOXC2 and VEGFR3 (i.e. primary
lymphedema), or from known causes, such as infection, trauma, and surgery (i.e. secondary
lymphedema). Unfortunately, there is no known cure or effective treatment available at the
moment. A fundamental approach to treat lymphedema would target new lymphatic vessel
growth by providing lymphangiogenic signals that can grow lymphatic vessels and/or
functional cells that can constitute lymphatic vessels. For example, VEGFC has been one of
the most extensively studied lymphangiogenic factors. Using mouse models for secondary
lymphedema and for wounds, the treatment of VEGFC either as a form of recombinant
protein or via several vehicles, such as viral vectors and naked plasmids, showed increased
lymphatic capillary formation, accompanied by reduced lymphedema (Saaristo et al., 2006;
Saaristo et al., 2004; Szuba et al., 2002; Yoon et al., 2003). Recent evidence also hinted such
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therapeutic potential by BM-derived cells. Conrad et al (2009) reported that human and
mouse MSCs express PROX-1 and enhance the expression of PODOPLANIN and
VEGFR-3 in culture with VEGFC or LEC-conditioned medium (Conrad et al., 2009). These
MSCs were shown to enhance lymphatic vessel growth and promote recovery from
lymphedema. Given the mounting evidence that BM-derived PODOPLANIN+ cells can
robustly induce lymphatic vessel growth through lymphangiogenesis and
lymphvasculogenesis, future studies should address whether PODOPLANIN+ cells can
attenuate or reverse lymphedema and intractable wound. One recent study reported that 9-cis
retinoic acid, which is involved in a variety of cellular events, was able to promote recovery
from lymphedema, at least, by activating the fibroblast growth factor (FGF) pathway (Choi
et al., 2012). It may also be interesting to investigate whether 9-cis retinoic acid may
augment LEPC action or mobilization on the foci of lymphatic vessel formation. One
concern with using LEPCs in patients with post-cancer lymphedema to promote new
lymphatic vessel formation is that dormant tumors may potentially grow or metastasize via
lymphatic vasculature (Sleeman and Thiele, 2009). Another concern is that LEPCs may
have potentially weak lymphvasculogenic effects, similar to the vasculogenic effects of
other bone marrow cells in blood vessel formation (Gothert et al., 2004; Larrivee et al.,
2005; Purhonen et al., 2008). However, we believe that the lymphatic endothelial cells lack
basement membrane and have simpler structures; so, the LEPC contribution to the increased
lymphatic vessel formation through lymphvasculogenesis may be more robust than EPC or
other BM cell contribution to blood vessel formation.
PODOPLANIN expressed in tumor cells has been used for detecting various types of tumors
and for evaluating their invasiveness, including kaposi sarcoma, hemangioendothelioma,
epithelioid methothelioma, and esophageal squamous cell carcinoma (Kalof and Cooper,
2009). Our study further showed that the number of BM and circulating PODOPLANIN+
cells in the mononuclear cell fraction can reflect the tumor burden in mice subcutaneously
implanted with melanoma cells or breast cancer cells. These data suggest that circulating
PODOPLANIN+ cells may be used as a biomarker to gauge the development and the
progression of certain types of tumors.
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Figure 1.
Lymphatic neovascularization mediated by BM-derived POD+CD11b+ cells.
Pathophysiologic conditions such as tumors or wounds can induce generation and
mobilization of POD+CD11b+ (POD+) LEPCs from BM to circulation, via growth factors or
cytokines, including VEGFA and VEGFC. Although the mechanisms by which BM-MNCs
or HSCs become POD+CD11b+ LEPCs need further investigation, the selective expression
of POD in CD11b+ myelomonocytes in response to environmental cues can confer CD11b+
cells to express stem/progenitor cell characteristics. Alternatively, POD+CD11b+ cells in
BM can be exclusively expanded in response to the above stimuli. The mobilized
POD+CD11b+ LEPCs migrate to peripheral tissues and contribute to new lymphatic vessel
formation through lymphvasculogenesis (i.e. LEPCs become LECs) and lymphangiogenesis
(i.e. LEPCs provide lymphangiogenic factors to enhance proliferation of pre-existing LECs).
POD; PODOPLANIN, HSCs; hematopoietic stem cells, BM-MNCs; bone marrow
mononuclear cells
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